Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy

1. Kepenekian, V. et al. Advances in the management of peritoneal malignancies. Nat. Rev. Clin. Oncol. 19, 698–718 (2022).

   Google Scholar 

2. Cortes-Guiral, D. et al. Primary and metastatic peritoneal surface malignancies. Nat. Rev. Dis. Prim. 7, 91 (2021).

   Google Scholar 

3. Coccolini, F. et al. Peritoneal carcinomatosis. World J. Gastroenterol. 19, 6979–6994 (2013).

   Google Scholar 

4. Cao, C. et al. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann. Surg. Oncol. 16, 2152–2165 (2009).

   Google Scholar 

5. Morano, W. F. et al. Intraperitoneal immunotherapy: historical perspectives and modern therapy. Cancer Gene Ther. 23, 373–381 (2016).

   Google Scholar 

6. Yao, X. et al. Molecular biology and immunology of gastric cancer peritoneal metastasis. Transl. Gastroenterol. Hepatol. 5, 57 (2020).

   Google Scholar 

7. Ornella, M. S. C. et al. Immunotherapy for peritoneal carcinomatosis: challenges and prospective outcomes. Cancers (Basel) 15, 2383 (2023).

   Google Scholar 

8. Kubicka, U. et al. Normal human immune peritoneal cells: subpopulations and functional characteristics. Scand. J. Immunol. 44, 157–163 (1996).

   Google Scholar 

9. Duan, Z. et al. Targeting macrophages in cancer immunotherapy. Signal Transduct. Target Ther. 6, 127 (2021).

   Google Scholar 

10. Biswas, S. K. et al. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896 (2010).

    Google Scholar 

11. Pittet, M. J. et al. Clinical relevance of tumour-associated macrophages. Nat. Rev. Clin. Oncol. 19, 402–421 (2022).

    Google Scholar 

12. Zhang, H. et al. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Mol. Cancer 22, 58 (2023).

    Google Scholar 

13. Hao, Y. et al. The CD47-SIRPalpha axis is a promising target for cancer immunotherapies. Int. Immunopharmacol. 120, 110255 (2023).

    Google Scholar 

14. Anderson, N. R. et al. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81, 1201–1208 (2021).

    Google Scholar 

15. Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019).

    Google Scholar 

16. Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286–299 (2009).

    Google Scholar 

17. Feng, Y. et al. A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages. Nat. Commun. 10, 2272 (2019).

    Google Scholar 

18. Zhang, F. et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 10, 3974 (2019).

    Google Scholar 

19. Jalil, A. R. et al. Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPalpha structure-function. Antib. Ther. 3, 80–94 (2020).

    Google Scholar 

20. Joshi, S. et al. Tim4 enables large peritoneal macrophages to cross-present tumor antigens at early stages of tumorigenesis. Cell Rep. 43, 114096 (2024).

    Google Scholar 

21. Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).

    Google Scholar 

22. Kang, M. et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv. Mater. 33, e2103258 (2021).

    Google Scholar 

23. Gao, L. et al. Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. J. Nanobiotechnol. 21, 56 (2023).

    Google Scholar 

24. Chen, C. et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci. Transl. Med 14, eabn1128 (2022).

    Google Scholar 

25. Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102–116 (2024).

26. Shen, J. et al. Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity. Cell Stem Cell 31, 1003–1019.e1009 (2024).

    Google Scholar 

27. Li, N. et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol. Cancer 23, 117 (2024).

    Google Scholar 

28. Blache, U. et al. Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nat. Commun. 13, 5225 (2022).

    Google Scholar 

29. Spanjaart, A. M. et al. Confused about confusion. N. Engl. J. Med. 386, 80–87 (2022).

    Google Scholar 

30. Lareau, C. A. et al. Latent human herpesvirus 6 is reactivated in CAR T cells. Nature 623, 608–615 (2023).

    Google Scholar 

31. Yang, Z. et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J. Control Release 360, 718–733 (2023).

    Google Scholar 

32. Poon, W. et al. A framework for designing delivery systems. Nat. Nanotechnol. 15, 819–829 (2020).

    Google Scholar 

33. Sindhwani, S. et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566–575 (2020).

    Google Scholar 

34. Taylor, P. R. et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat. Immunol. 8, 31–38 (2007).

    Google Scholar 

35. Theobald, H. et al. Apolipoprotein E controls dectin-1-dependent development of monocyte-derived alveolar macrophages upon pulmonary beta-glucan-induced inflammatory adaptation. Nat. Immunol. 25, 994–1006 (2024).

36. Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47–58 (2020).

    Google Scholar 

37. Liu, P. S. et al. CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions. Nat. Immunol. 24, 452–462 (2023).

    Google Scholar 

38. Kagan, J. C. et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 9, 361–368 (2008).

    Google Scholar 

39. Luozhong, S. et al. Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs. Nano Lett. 22, 8304–8311 (2022).

    Google Scholar 

40. Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).

    Google Scholar 

41. Li, W. et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity 53, 456–470.e456 (2020).

    Google Scholar 

42. Candas-Green, D. et al. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat. Commun. 11, 4591 (2020).

    Google Scholar 

43. Upton, R. et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc. Natl. Acad. Sci. USA 118, e202684911 (2021).

    Google Scholar 

44. Weiskopf, K. et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88–91 (2013).

    Google Scholar 

45. Hoch, T. et al. Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Sci. Immunol. 7, eabk1692 (2022).

    Google Scholar 

46. Reschke, R. et al. CXCL9 and CXCL10 bring the heat to tumors. Sci. Immunol. 7, eabq6509 (2022).

    Google Scholar 

47. Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of Anti-PD-1 therapy. Immunity 50, 1498–1512.e1495 (2019).

    Google Scholar 

48. Oh, S. A. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat. Cancer 1, 681–691 (2020).

    Google Scholar 

49. Peng, Q. et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat. Commun. 11, 4835 (2020).

    Google Scholar 

50. Gu, S. S. et al. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov. 11, 1524–1541 (2021).

    Google Scholar 

51. Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421 (2016).

    Google Scholar 

52. Tsui, C. et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature 609, 354–360 (2022).

    Google Scholar 

53. Siddiqui, I. et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211.e110 (2019).

    Google Scholar 

54. Guerriero, J. L. Macrophages: their untold story in T cell activation and function. Int. Rev. Cell Mol. Biol. 342, 73–93 (2019).

    Google Scholar 

55. Pierini, S. et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat. Commun. 16, 706 (2025).

    Google Scholar 

56. Qu, T. et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J. Immunother. Cancer 10, e005517 (2022).

    Google Scholar 

57. Yu, J. et al. SIRPalpha-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPalpha signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal. J. Hematol. Oncol. 15, 167 (2022).

    Google Scholar 

58. Trouplin, V. et al. Bone marrow-derived macrophage production. J. Vis. Exp. 81, e50966 (2013).

59. Andries, O. et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control Release 217, 337–344 (2015).

    Google Scholar 

60. Miao, L. et al. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nat. Commun. 11, 2424 (2020).

    Google Scholar 

61. Paradis, E. et al. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. Bioinformatics 35, 526–528 (2019).

    Google Scholar 

Download references

Authors and Affiliations

1. Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China

   Kedan Gu, Ting Liang, Luting Hu, Yifan Zhao, Weiyang Ying, Mengke Zhang, Yashuang Chen, Hongyu Wu, Meng Wang, Yuping Zhu, Wenxi Wang, Yu Zhang, Chao Zuo, Zhen Du, Penghui Zhang, Liwen Li, Xiangsheng Liu, Sitao Xie & Weihong Tan

2. School of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China

   Kedan Gu, Wenxi Wang, Yu Zhang, Chao Zuo, Zhen Du, Penghui Zhang, Xiangsheng Liu, Sitao Xie & Weihong Tan

3. Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, College of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai, China

   Benmeng Liang, Xinrui Lin, Yanqi Zhang & Jia Song

4. Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China

   Yu Zhang, Chao Zuo & Sitao Xie

5. Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, China

   Sitao Xie

Contributions

Conceptualization: K.G., X.L., S.X. and W.T. Methodology: T.L., L.H., Y.Z., W.Y., M.Z., Y.C., H.W., M.W., Y.Z., C.Z., W.W., Z.D., L.L. and P.Z. Data analysis: B.L., S.L., Y.Z., and J.S. Funding acquisition and Supervision: X.L., S.X. and W.T. Writing–original draft & review & editing: K.G., X.L., S.X. and W.T.

Corresponding authors

Correspondence to Xiangsheng Liu, Sitao Xie or Weihong Tan.

Competing interests

The authors have filed a patent application (CN202410159815.8; Title: Methods for generating multifunctional CAR-Ms in situ and their application in immunotherapy; W.T., S.X., K.G., X.L., P.Z. and C.Z. are co-inventors) for some aspects of this work. The authors declare no competing interests.

Peer review information

Nature Communications thanks Marie Duhamel, Enzo Medico, Alice Dandrea and the other anonymous reviewer(s) for their contribution to the peer review of this work. [A peer review file is available].

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions